deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01372228

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

Sponsor: Duke University

Conditions Adrenoleukodystrophy (ALD and AMN) Alpha-mannosidosis Hunter Syndrome (MPS II) Hurler Syndrome (MPS I) Hurler-Scheie Syndrome Krabbe Disease (Globoid Leukodystrophy) Metachromatic Leukodystrophy (MLD) Niemann-Pick Disease Pelizaeus Merzbacher (PMD) Sandhoff Disease Sanfilippo Syndrome (MPS III) Tay Sachs Disease
Interventions hematopoietic stem cell infusion
Updated 14 times since 2017 Last updated: Apr 10, 2023 Started: Apr 30, 2011 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

company did not pursue this indication

Other terminated trials from Duke University

See all terminations from Duke University

A PHASE1/PHASE2 clinical study on Adrenoleukodystrophy (ALD and AMN) and Alpha-mannosidosis, this trial is terminated or withdrawn. The trial is conducted by Duke University and has accumulated 14 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Oct 2019 · 9 months · monthly snapshot~Oct 2019 – ~Nov 2020 · 13 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Apr 2023 — May 2023 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  5. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Oct 2019 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jun 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jul 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Duke University
  • Talaris Therapeutics Inc.
Data source: Talaris Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations